• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

慢性粒细胞白血病，一个仍未解决的问题：陷阱与新的治疗可能性。

Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities.

作者信息

Flis Sylwia, Chojnacki Tomasz

机构信息

Department of Pharmacology, National Medicines Institute, 00-725 Warsaw, Poland,

Department of Hematology, Military Institute of Medicine, 04-141 Warsaw, Poland,

出版信息

Drug Des Devel Ther. 2019 Mar 8;13:825-843. doi: 10.2147/DDDT.S191303. eCollection 2019.

DOI:10.2147/DDDT.S191303
PMID:30880916
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6415732/
Abstract

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of hematopoietic stem cells. At the molecular level, the disorder results from t(9;22)(q34;q11) reciprocal translocation between chromosomes, which leads to the formation of an oncogenic gene fusion. Instead of progress in the understanding of the molecular etiology of CML and the development of novel therapeutic strategies, clinicians still face many challenges in the effective treatment of patients. In this review, we discuss the pathways of diagnosis and treatment of patients, as well as the problems appearing in the course of disease development. We also briefly refer to several aspects regarding the current knowledge on the molecular basis of CML and new potential therapeutic targets.

摘要

慢性髓系白血病（CML）是一种造血干细胞的克隆性骨髓增殖性疾病。在分子水平上，该疾病源于染色体之间的t(9;22)(q34;q11)相互易位，这导致了致癌基因融合的形成。尽管在慢性髓系白血病分子病因的理解以及新型治疗策略的开发方面取得了进展，但临床医生在有效治疗患者方面仍面临许多挑战。在本综述中，我们讨论了患者的诊断和治疗途径，以及疾病发展过程中出现的问题。我们还简要提及了关于慢性髓系白血病分子基础的当前知识和新的潜在治疗靶点的几个方面。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9054/6415732/6a037d9289ea/dddt-13-825Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9054/6415732/0df61ed05739/dddt-13-825Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9054/6415732/6a037d9289ea/dddt-13-825Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9054/6415732/0df61ed05739/dddt-13-825Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9054/6415732/6a037d9289ea/dddt-13-825Fig2.jpg

相似文献

1
Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities.慢性粒细胞白血病，一个仍未解决的问题：陷阱与新的治疗可能性。
Drug Des Devel Ther. 2019 Mar 8;13:825-843. doi: 10.2147/DDDT.S191303. eCollection 2019.
2
Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.酪氨酸激酶抑制剂时代的慢性髓性白血病：分子靶向治疗的不断演变模式
Mol Diagn Ther. 2016 Aug;20(4):315-33. doi: 10.1007/s40291-016-0208-1.
3
BCR-ABL inhibitors in chronic myeloid leukemia: process chemistry and biochemical profile.BCR-ABL 抑制剂在慢性髓性白血病中的应用：工艺化学和生化特征。
Curr Med Chem. 2011;18(19):2943-59. doi: 10.2174/092986711796150414.
4
Chronic Myeloid Leukemia (CML) Mouse Model in Translational Research.转化研究中的慢性髓性白血病（CML）小鼠模型
Methods Mol Biol. 2016;1438:225-43. doi: 10.1007/978-1-4939-3661-8_13.
5
Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase.降解剂与抑制剂针对致癌性 BCR-ABL 激酶的药理学差异。
Sci Rep. 2018 Sep 10;8(1):13549. doi: 10.1038/s41598-018-31913-5.
6
BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.未接受过酪氨酸激酶抑制剂治疗和已暴露于酪氨酸激酶抑制剂的东南亚慢性髓性白血病患者的 BCR-ABL 激酶结构域突变。
Exp Mol Pathol. 2012 Apr;92(2):259-65. doi: 10.1016/j.yexmp.2012.01.007. Epub 2012 Jan 31.
7
[New approach in the diagnosis and monitoring of treatment in chronic myelogenous leukemia].[慢性粒细胞白血病诊断与治疗监测的新方法]
Orv Hetil. 2004 Dec 26;145(52):2603-9.
8
Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.miR-424 的恢复抑制了 BCR-ABL 的活性，并使 CML 细胞对伊马替尼治疗敏感。
Cancer Lett. 2015 May 1;360(2):245-56. doi: 10.1016/j.canlet.2015.02.031. Epub 2015 Feb 16.
9
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy.隐匿性BCR-ABL融合基因作为慢性髓性白血病的变异重排：分子细胞遗传学特征及其对酪氨酸激酶抑制剂治疗的影响
Oncotarget. 2017 May 2;8(18):29906-29913. doi: 10.18632/oncotarget.15369.
10
Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.三种新型患者源性 BCR/ABL 突变体对第二代和第三代酪氨酸激酶抑制剂表现出不同的敏感性。
Am J Hematol. 2012 Nov;87(11):E125-8. doi: 10.1002/ajh.23338. Epub 2012 Oct 9.

引用本文的文献

1
Synthesis, characterization, and evaluation of the cytotoxic effects of caffeine nanoparticles on K562 cancer cell line.咖啡因纳米颗粒对K562癌细胞系细胞毒性作用的合成、表征及评估
Med Oncol. 2025 May 31;42(7):229. doi: 10.1007/s12032-025-02784-4.
2
Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in South Africa.南非慢性粒细胞白血病酪氨酸激酶抑制剂治疗策略的成本效益
Front Pharmacol. 2025 Jan 7;15:1511603. doi: 10.3389/fphar.2024.1511603. eCollection 2024.
3
Anti-Leukemic Effects of Small Molecule Inhibitor of c-Myc (10058-F4) on Chronic Myeloid Leukemia Cells.

本文引用的文献

1
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia.非 ABL 靶向抑制剂作为慢性髓性白血病的替代治疗策略。
Mol Cancer. 2018 Feb 19;17(1):56. doi: 10.1186/s12943-018-0805-1.
2
Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment.简明综述：慢性髓性白血病：干细胞生态位与药物治疗反应。
Stem Cells Transl Med. 2018 Mar;7(3):305-314. doi: 10.1002/sctm.17-0175. Epub 2018 Feb 8.
3
Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy.
c-Myc 小分子抑制剂（10058-F4）对慢性髓性白血病细胞的抗白血病作用。
Asian Pac J Cancer Prev. 2024 Jun 1;25(6):1959-1967. doi: 10.31557/APJCP.2024.25.6.1959.
4
Atypical -Alkyl to -Noralkoxy Switch in a Dual cSRC/BCR-ABL1 Kinase Inhibitor Improves Drug Efflux and hERG Affinity.双cSRC/BCR-ABL1激酶抑制剂中典型的烷基到去甲烷氧基转换改善了药物外排和人醚-à-去极化相关基因（hERG）亲和力。
ACS Med Chem Lett. 2023 Dec 5;14(12):1869-1875. doi: 10.1021/acsmedchemlett.3c00479. eCollection 2023 Dec 14.
5
Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines.姜黄素降低伊马替尼敏感和伊马替尼耐药的慢性髓性白血病细胞系的活力并抑制其增殖。
Metabolites. 2022 Dec 30;13(1):58. doi: 10.3390/metabo13010058.
6
A Systematic Literature Review of the Economic Evaluations of Treatments for Patients with Chronic Myeloid Leukemia.慢性髓性白血病患者治疗的经济评估系统文献综述。
Pharmacoeconomics. 2022 Dec;40(12):1159-1186. doi: 10.1007/s40273-022-01189-9. Epub 2022 Sep 30.
7
Critical Requirement of SOS1 for Development of BCR/ABL-Driven Chronic Myelogenous Leukemia.SOS1对BCR/ABL驱动的慢性粒细胞白血病发展的关键需求。
Cancers (Basel). 2022 Aug 11;14(16):3893. doi: 10.3390/cancers14163893.
8
Integrated genomic sequencing in myeloid blast crisis chronic myeloid leukemia (MBC-CML), identified potentially important findings in the context of leukemogenesis model.在骨髓增生异常综合征伴原始细胞增多的慢性髓系白血病（MBC-CML）的整合基因组测序中，确定了在白血病发生模型背景下具有潜在重要意义的发现。
Sci Rep. 2022 Jul 27;12(1):12816. doi: 10.1038/s41598-022-17232-w.
9
Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells.酮康唑逆转人慢性髓系白血病 K562 细胞对伊马替尼的耐药性。
Int J Mol Sci. 2022 Jul 13;23(14):7715. doi: 10.3390/ijms23147715.
10
Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia.慢性髓性白血病的耐药机制及其对治疗策略的影响
Cancers (Basel). 2022 Jul 6;14(14):3300. doi: 10.3390/cancers14143300.
在酪氨酸激酶抑制剂（TKI）治疗时代，基于细胞遗传学的慢性髓性白血病急变风险预测
Blood Adv. 2017 Dec 8;1(26):2541-2552. doi: 10.1182/bloodadvances.2017011858. eCollection 2017 Dec 12.
4
New Opportunities and Challenges to Defeat Cancer Stem Cells.战胜癌症干细胞的新机遇与挑战。
Trends Cancer. 2017 Nov;3(11):780-796. doi: 10.1016/j.trecan.2017.08.007. Epub 2017 Sep 21.
5
Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options.慢性髓性白血病中的表观遗传失调：众多的机制和治疗选择。
Semin Cancer Biol. 2018 Aug;51:180-197. doi: 10.1016/j.semcancer.2017.07.006. Epub 2017 Aug 2.
6
Molecular mechanisms and physiological roles of Atg5/Atg7-independent alternative autophagy.Atg5/Atg7非依赖性选择性自噬的分子机制及生理作用
Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(6):378-385. doi: 10.2183/pjab.93.023.
7
Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.双重PI3K和mTOR抑制剂NVP-BEZ235联合甲磺酸伊马替尼对慢性粒细胞白血病细胞系的疗效。
Drug Des Devel Ther. 2017 Apr 3;11:1115-1126. doi: 10.2147/DDDT.S132092. eCollection 2017.
8
MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.MPT0B002，一种新型的微管抑制剂，下调 T315I 突变型 Bcr-Abl 并诱导伊马替尼耐药慢性髓系白血病细胞凋亡。
Invest New Drugs. 2017 Aug;35(4):427-435. doi: 10.1007/s10637-017-0457-9. Epub 2017 Mar 27.
9
Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.β-连环蛋白和Bcr-Abl的联合抑制在体外和体内协同靶向酪氨酸激酶抑制剂耐药的急变期慢性髓性白血病母细胞和祖细胞。
Leukemia. 2017 Oct;31(10):2065-2074. doi: 10.1038/leu.2017.87. Epub 2017 Mar 21.
10
Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia.抑制自噬可增强替加环素的选择性抗癌活性，以克服慢性髓性白血病治疗中的耐药性。
J Exp Clin Cancer Res. 2017 Mar 10;36(1):43. doi: 10.1186/s13046-017-0512-6.